| Company | Products | Press | Purchase | Contact |
Company Profile
Biopharmaceutical company developing enhanced natural therapeutics for infectious diseases, cancer and and quality-of-life medicines
Enhanced therapeutics include small molecules from medicinal plants and marine organisms, and improved drug delivery formulations of protein macromolecules and hydrophobic anticancer drugs
Enabling technology platforms, nanotechnologies and therapeutic products covered by 29 issued U.S. and international patents, and several pending patent applications
History of collaborations with multinational companies such as Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly and the Gillette Company, and leading academic institutions
Product Pipeline
Six lead therapeutic products being developed: an antidepressant, a benign prostatic hyperplasia product and four oncology products – LoTax™, a generic of the popular anticancer drug Taxol®, two improved drug delivery formulations of paclitaxel and Zindol™, an enhanced ginger product, in a Phase II/III clinical trial for nausea in cancer patients undergoing chemotherapy
Business Strategy
Collaborative R&D with strategic corporate partners to develop enhanced therapeutic products
Licensure of enabling technology platforms for the discovery, delivery and development of small natural molecules and large protein macromolecules
Direct product sales of active pharmaceutical ingredients (APIs) and finished products
For more information about Aphios Corporation, please click here.
Home l Company l Products l Press l Purchase l Contact ©
2006 Aphios® Corporation |